Gilead Sciences, Inc. $GILD Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,055,394 shares of the biopharmaceutical company’s stock after selling 38,756 shares during the period. New York State Teachers Retirement System’s holdings in Gilead Sciences were worth $129,539,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA lifted its holdings in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after acquiring an additional 4,113,999 shares during the period. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after buying an additional 2,113,692 shares during the period. First Trust Advisors LP boosted its position in Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares during the period. Invesco Ltd. increased its holdings in Gilead Sciences by 12.0% in the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in Gilead Sciences in the 3rd quarter valued at $133,049,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock opened at $130.84 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The stock’s 50 day simple moving average is $140.49 and its 200 day simple moving average is $132.35. The firm has a market cap of $162.40 billion, a P/E ratio of 19.33, a P/E/G ratio of 1.70 and a beta of 0.39. Gilead Sciences, Inc. has a 12-month low of $95.29 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the previous year, the business earned $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 8.62 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a $0.82 dividend. The ex-dividend date was Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.5%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: FDA granted priority review for Gilead’s once?daily bictegravir + lenacapavir HIV single?tablet regimen, with a PDUFA action date in August—this materially shortens the timeline to U.S. commercialization if approved and is a clear near?term revenue/catalyst driver. U.S. FDA Grants Priority Review
• Positive Sentiment: Morgan Stanley raised its price target to $175 and maintained an Overweight rating — a high?profile analyst upgrade that can attract institutional and momentum buying. Morgan Stanley Price Target Raise
• Positive Sentiment: Gilead completed the acquisition of Arcellx (~$7.8B), adding the anito?cel cell therapy to its oncology pipeline — expands long?term growth optionality beyond antivirals. Gilead Completes Arcellx Acquisition
• Positive Sentiment: Coverage and market writeups are bullish ahead of earnings — analysts and outlets flag a combination of beat potential and multi?year technical breakout narratives that can fuel momentum flows. Wall Street Outlook
• Neutral Sentiment: Gilead announced several upcoming investor presentations (BofA, RBC, Bernstein, Goldman Sachs) in May — opportunities to refresh guidance/MSG to investors but not immediate revenue drivers. Investor Conference Schedule
• Neutral Sentiment: Estimates tweaked: Erste Group trimmed FY2026 EPS slightly but lifted FY2027 — minor modeling adjustments that leave consensus largely intact. Erste Group Estimate Changes
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (~$1.29M) under a pre?arranged 10b5?1 plan. Insider sales can create short?term headline pressure despite being routine and pre?planned. CEO Insider Sale Filing
• Negative Sentiment: Advocacy group AHF filed a shareholder resolution seeking greater transparency on patent exclusivities — introduces governance/IP scrutiny that could raise uncertainty around exclusivity?dependent revenues. AHF Shareholder Resolution

Analyst Ratings Changes

A number of research analysts have commented on the company. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 price objective on shares of Gilead Sciences in a research note on Wednesday, February 11th. Barclays initiated coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an “equal weight” rating and a $155.00 target price for the company. Deutsche Bank Aktiengesellschaft boosted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, February 11th. Argus upped their price target on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Finally, Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $118.00 to $123.00 and gave the company a “sector perform” rating in a research note on Tuesday, April 7th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total value of $422,880.00. Following the transaction, the insider owned 128,779 shares of the company’s stock, valued at $18,152,687.84. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares in the company, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 178,640 shares of company stock worth $26,584,250 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.